Canopy Growth Corporation (NASDAQ: CGC) on Friday, plunged -4.65% from the previous trading day, before settling in for the closing price of $1.29. Within the past 52 weeks, CGC’s price has moved between $0.77 and $2.90.
Annual sales at Healthcare sector company grew by 32.50% over the past five years. The company achieved an average annual earnings per share of 91.84%. With a float of $340.75 million, this company’s outstanding shares have now reached $342.20 million.
Canopy Growth Corporation (CGC) Insider Updates
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Canopy Growth Corporation is 0.43%, while institutional ownership is 10.27%. The most recent insider transaction that took place on Dec 31 ’25, was worth 11,790. In this transaction Director of this company sold 10,434 shares at a rate of $1.13, taking the stock ownership to the 63,518 shares. Before that another transaction happened on Dec 31 ’25, when Company’s Director sold 15,715 for $1.13, making the entire transaction worth $17,758. This insider now owns 87,672 shares in total.
Canopy Growth Corporation (CGC) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.06 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.23) by -0.83. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 91.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 76.27% during the next five years compared to 32.50% growth over the previous five years of trading.
Canopy Growth Corporation (NASDAQ: CGC) Trading Performance Indicators
Canopy Growth Corporation (CGC) is currently performing well based on its current performance indicators. A quick ratio of 4.23 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.95, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.19 in one year’s time.
